{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-004220","form_type":"8-K","ticker":"ZSQR","cik":"0001759186","company_name":"Z Squared Inc.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.418506+00:00","generated_at":"2026-06-13T22:59:16.078317+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Coeptis Therapeutics closes $3.5M underwritten offering of common stock and warrants","bullets":["Offering gross proceeds ~$3.5M before expenses; closed June 16, 2023 to a single healthcare investor.","Components: 2,150,000 shares, 1,350,000 pre-funded warrants at $0.0001, 3,062,500 Series A and 3,062,500 Series B warrants at $1.65.","Series A and B warrants exercisable for five years starting six months after issuance; fixed pricing with no resets.","Ladenburg Thalmann acted as sole book-running manager; lock-up of 75 days for company and insiders."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-004220","json":"https://secwatch.observer/filing/0001683168-23-004220.json","markdown":"https://secwatch.observer/filing/0001683168-23-004220.md","text":"https://secwatch.observer/filing/0001683168-23-004220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759186/000168316823004220/0001683168-23-004220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759186/000168316823004220/coeptis_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:59:16.078317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"683debb271faca5934abebc8ab8e5be93b35de6f","claim":"Z Squared Inc. entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. valued at approximately $3.5 million (effective 2023-06-13).","evidence_excerpt":"On June 13, 2023, Coeptis Therapeutics Holdings, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Underwriter”), pursuant to which the Company issued and sold, in a registered public offering by the Company (the “Offering”) (i) 2,150,000 shares of common stock (the “Shares”), (ii) 1,350,000 pre-funded warrants (the “Pre-funded Warrants”), (iii) 3,062,500 Series A Warrants with an exercise price of $1.65 per share and which are exercisable for a period of five years commencing six months after the issuance date (the “Series A Warrants”), and (iv) 3,062,500 Series B Warrants with an exercise price of $1.65 per share and which are exercisable for a period of five years commencing six months after the issuance date (the “Series B Warrants, and together with the Pre-funded Warrants and the Series B Warrants, the “Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759186/000168316823004220/0001683168-23-004220-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Ladenburg Thalmann & Co. Inc."},{"label":"Value","value":"approximately $3.5 million"},{"label":"Effective","value":"2023-06-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}